Design of a doxorubicin-peptidomimetic conjugate that targets HER2-positive cancer cells.

Pallerla, Sandeep; Gauthier, Ted; Sable, Rushikesh; Jois, Seetharama D

Pallerla, Sandeep; Gauthier, Ted; Sable, Rushikesh; Jois, Seetharama D.

Afiliação

Pallerla S; Department of Basic Pharmaceutical Sciences, School of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71201, United States.
Gauthier T; Biotechnology Laboratory, LSU AgCenter, Louisiana State University, Baton Rouge, LA 70803, United States.
Sable R; Department of Basic Pharmaceutical Sciences, School of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71201, United States.
Jois SD; Department of Basic Pharmaceutical Sciences, School of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71201, United States. Electronic address: jois@ulm.edu.

Eur J Med Chem ; 125: 914-924, 2017 Jan 05.

Article em En | MEDLINE | ID: mdl-27769032

Assuntos

Antineoplásicos/farmacocinética; Doxorrubicina/farmacologia; Peptidomiméticos/farmacologia; Receptor ErbB-2/análise; Antineoplásicos/química; Antineoplásicos/farmacologia; Sítios de Ligação; Doxorrubicina/química; Doxorrubicina/farmacocinética; Feminino; Meia-Vida; Humanos; Células MCF-7; Peptidomiméticos/química; Peptidomiméticos/farmacocinética; Ligação Proteica

Palavras-chave

Breast cancer; Conjugate; Doxorubicin; HER2; Lung cancer; Peptidomimetic

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doxorrubicina / Receptor ErbB-2 / Peptidomiméticos / Antineoplásicos Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google